PHIO stock soars during current market trading. Here’s to know why?

TDOC Stock
TDOC Stock

Phio Pharmaceuticals Inc. (NASDAQ: PHIO) stock gains by 13.96% in the current market trading session. Phio Pharmaceuticals Corp. is a biotechnology business working on the next generation of immuno-oncology medicines using their INTASYSL (self-delivering RNAi) therapeutic system. The objective is to generate INTASYL therapeutic chemicals that can be used to weaponize immune effector cells and defeat tumour immune evasion.

PHIO stock’ Significant Development

Phio Pharmaceuticals released the findings of a new research showing that local treatment in vivo with INTASYL can cure tumours and develop long-lasting, tumor-specific systemic tumour immunity. These findings, which were published at the European Society of Medical Oncology (ESMO) Congress 2021, demonstrate the INTASYL technology’s promise in direct therapeutic applications.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


In a preclinical in vivo hepatocellular carcinoma model, the research was conducted to demonstrate the synergistic effect of co-targeting PD-1 and BRD4 using one INTASYL formulation (PH-3861). The findings demonstrate that when animals were given low doses of PH-3861, such as levels that were not optimal for monotherapy, up to 83 percent of them exhibited a full response. Furthermore, this treatment elicited a long-lasting and targeted anti-tumor immune response that did not require subsequent treatment.


Subcutaneous Hepa1-6 tumours in mice were cured with a murine form of dual targeting INTASYL PH-3861 (mPH-3861) by local injection to the tumour at low dosages that are inappropriate for a single drug targeting either PD-1 or BRD4 alone, according to the findings reported today. Mice that were completely cured of tumours with mPH-3861 were re-challenged 2.5 months later by implanting hepatoma cancer cells in a different site than the previous tumor challenge. All of the re challenged mice that had previously been cured by mPH-3861 were cured without the need for further therapy, but tumours in the control group developed slowly as expected. These findings reveal that mPH-3861 therapy induces a long-lasting and systemic anti-tumor immune response that can stop tumour growth.


Please enter your comment!
Please enter your name here